Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
about
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.Treating haemophilia A with recombinant blood factors: a comparison.Safety and supply of haemophilia products: worldwide perspectives.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH.2017 Clinical trials update: Innovations in hemophilia therapy.In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis.Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding.Meta-analytic evidence of increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII.B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
P2860
Q34283156-79B7F1E5-F28A-4D3C-BF5A-68D8C27E747BQ35778288-DFA98016-F880-4581-AD70-E76D4E462A09Q35779195-21CC66A8-B169-4AE0-B1CB-4CB701D64967Q35824847-77154033-E91F-4127-9155-0F1BD0BDB5A5Q37230340-77328D5A-7053-4885-9262-1C6D2BA7EE8DQ38833988-68D1E95C-5ECF-411E-9ED7-22F8A08E3C8CQ38937725-4245AE0F-7D01-4AC1-99DE-DB7EF7DE09C4Q39223784-92D9085A-1C57-4FF7-A463-4CB519E414D3Q39475869-A3FE164F-385F-4234-A8CB-E33FBE4810F1Q40216648-AB4ECD5B-C9FD-4058-B0E5-8730E92B184FQ43684691-DFCF11F2-043C-45BB-93C5-ED4895655819Q45865789-6706C58D-E171-4926-94DC-27BEFC06AC7EQ45872099-A88B1473-5B14-4B35-9C29-F936F1556464Q45877725-47D1EBF5-D8BB-400D-ABC6-5ECC67DF5DBAQ45879776-A7C0DD83-BC56-47A1-82CC-025DED1BD60FQ45882434-5076DA1E-BCF3-464A-933B-7FCCF2971D7AQ45886350-B96EFA95-9BAE-4A2A-B90B-D89EB09093CEQ57179210-796D55F2-64DF-477C-A1A0-A8B64B5BDBB9
P2860
Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@ast
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@en
type
label
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@ast
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@en
prefLabel
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@ast
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@en
P2093
P2860
P1433
P1476
Comparative effectiveness of f ...... prophylaxis--a meta-analysis.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2516.2003.00769.X
P577
2003-05-01T00:00:00Z